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Abstract 
Background: Pharmacovigilance activities are in a developing stage in Nepal. ADR reporting is mainly confined 
to healthcare professionals working in institutions recognized as regional pharmacovigilance centers. Community 
pharmacists could play an important role in pharmacovigilance. This study was conducted among community 
pharmacists in Lalitpur district to examine their knowledge and attitude about pharmacovigilance before and after an 
educational intervention.
Methods: Knowledge and attitude was studied before, immediately after and 6 weeks following the intervention 
among 75 community pharmacists. Responses were analysed using descriptive and inferential statistics. A pretested 
questionnaire having twelve and nine statements for assessing knowledge and attitude were used. The overall scores 
were obtained by adding the ‘knowledge’ and ‘attitude’ scores and ‘overall’ scores were summarized using median and 
interquartile range. Wilcoxon signed-rank test for repeated samples was used to compare the differences between 
knowledge and attitude of the pharmacists before and after the educational program.
Results: Knowledge scores [median (interquartile range)] improved significantly between pre-test [39 (44–46)], 
post-test [44 (44–44)] and retention period of 6 weeks after the intervention [46 (43–46)]. Knowledge score improved 
immediately post-intervention among both males [44 (41–47)] and females [44 (43–45)] but the retention scores 
(after 6 weeks) were higher [46 (42–48)] among males. Attitude scores improved significantly among females [46 
(44–48)]. The overall scores were higher among pharmacists from rural areas.
Conclusion: Knowledge and attitude scores improved after the educational intervention. Further studies in other 
regions of the country are required. The national pharmacovigilance center should promote awareness about ADR 
reporting among community pharmacists.
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Background
Adverse drug reactions (ADRs) can be a serious threat 
to the health of the Nepalese population as a variety of 
medicines like, allopathic, traditional, homeopathic 
and ayurvedic are available in ever increasing amounts. 
Strengthening the ADR reporting system, and making 
ADR reporting by health professionals mandatory can 
be useful but unfortunately reporting is not mandatory 
according to the laws and regulations of Nepal [1]. Vol-
untary reporting of ADRs by healthcare professionals 
(HCPs) is limited [2]. There is no involvement of com-
munity pharmacists (CPs) in the existing ADR reporting 
system [3]. In the Pokhara valley in western Nepal, a pilot 
program was conducted to train selected CPs in ADR 
reporting and pharmacovigilance [4]. During the study 
period 71 ADRs were reported by the CPs. However, 
there has been no further development of ADR reporting 
by CPs.
Nepal is situated between India and China and is 
divided into mountainous region, hilly region and plain 
terrain. The difficult terrain causes problems for the pop-
ulation in accessing healthcare facilities. The total popu-
lation of Nepal in 2011 was 26.5 million [3]. The GDP per 
capita was US$ 562. Population below 15 years was 37% 
and above 60  years was 6% of the total population [5]. 
Urban population was 28.1% of the total population [6]. 
Adult literacy rate was 65.9% [7].
Nepal produces a significant number of doctors and 
other health personnel but only a low number stay back 
as they get better opportunities in the developed world. 
This brain drain has resulted in a very poor doctor popu-
lation, pharmacist population and nurse population ratio. 
There are 10,197 (3.64/10,000 population) medical and 
dental doctors, 32,846 (11.71/10,000 population) nursing 
and midwifery personnel and 731 (0.261/10,000 popula-
tion) licensed pharmacists in Nepal [8]. This low ratio of 
HCP to patients can result in increased workload creat-
ing difficulty in sparing time for ADR reporting. This 
could be an important reason for underreporting by 
HCPs in Nepal. Underreporting remains a big problem 
worldwide among HCPs [9–11]. The pharmacist popu-
lation ratio in Nepal is 0.3/10,000 while the community 
pharmacist population ratio is only 0.013/10,000 [8].
Pharmacy practice in the community
Doctors do not practice in many remote and rural areas 
of Nepal. The population depends on local practitioners 
and community pharmacies for healthcare and a large 
number of community pharmacies have been established. 
The number of pharmacies is greater than the number of 
health centres [12, 13]. Community pharmacists do not 
charge consultation fees unlike medical doctors. This 
may be a factor responsible for these pharmacies being 
the first point of contact with the healthcare system for 
the general public. These factors support and encour-
age self-medication in the country [13, 14] which may 
increase the incidence of ADRs.
The number of qualified pharmacists in community 
pharmacies, capable of delivering quality pharmaceuti-
cal services is inadequate [15]. As per the Drug Act of 
1978, pharmacists, assistant pharmacists and pharmacy 
professionals are eligible to work in a community phar-
macy after registering with the national drug regula-
tory authority, the Department of Drug Administration 
(DDA) [16].
Pharmacists working in community pharmacies have 
completed either a three year Diploma in Pharmacy 
(DPharm) after ten years of schooling (assistant phar-
macists), or four year Bachelor in Pharmacy (BPharm) 
degree after twelve years of schooling (pharmacists). 
However, some have only completed a training and ori-
entation program of 2 weeks, conducted by DDA (phar-
macy professionals) [17, 18]. Only pharmacists and 
assistant pharmacists are eligible for registering with the 
Pharmacy Council of Nepal [19].
In Nepal with a high prevalence of self-medication and 
non-doctor prescribing, it is important to expand the 
existing pharmacovigilance system to involve community 
pharmacists [1, 14, 20]. A community-based ADR report-
ing system can play an active role in collecting reports of 
ADRs occurring in the community [3, 4].
Pharmacovigilance activities in Nepal
Nepal was recognized as a member of the International 
Pharmacovigilance Programme in 2007. The national 
pharmacovigilance centre run by the DDA, coordinates 
with seven regional pharmacovigilance centres to collect 
ADR reports which are forwarded to the Uppsala Moni-
toring Centre in Sweden, a centre for international ser-
vice and scientific research towards patient safety [21]. 
Till date, the ADR reporting system does not involve 
community pharmacists and consumers and depends on 
voluntary reporting from other healthcare professionals, 
predominantly doctors, hospital pharmacists and nurses 
[22].
Rationale of the study
Factors like knowledge about medicines, cost of medi-
cines, regulatory systems, laws, cultural issues and com-
munity beliefs can influence medicine use by consumers. 
They can also be influenced by the commercial promo-
tion of medicines and communication with the pre-
scriber and dispenser [20]. Nepal has many medicine 
use problems, for example: polypharmacy, use of expired 
drugs, irrational combination drugs, and overuse of anti-
biotics, vitamins/herbal remedies and prescribing using 
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brand names [13, 14]. These combined with lack of infor-
mation to patients about the proper handling and use of 
drugs can lead to serious consequences like ADRs and 
interactions [14]. Studies show that community pharma-
cists may have an important role in pharmacovigilance 
[3, 23]. To participate effectively however, community 
pharmacists should have adequate knowledge and proper 
attitudes towards pharmacovigilance. The present study 
has the objective of evaluating knowledge and attitude 
of community pharmacists regarding pharmacovigilance 
and consumer pharmacovigilance and compares the 
scores among different subgroups before, immediately 
after and six weeks following an educational intervention.
Methods
Study site and study period
The study was conducted from August 2014 to June 2015 
among community pharmacists in Lalitpur district, one 
of the seventy-five districts of Nepal. The district, with 
Patan as its headquarters, covers an area of 385  km2 
and is one of the three districts in the Kathmandu Val-
ley, along with Kathmandu and Bhaktapur. Its population 
was 466,784 in the initial 2011 census tabulation [7]. Lal-
itpur District has two medical colleges, various other col-
leges and other institutions of higher learning [7].
Study design
The design was cross sectional conducted at three points 
in time, before, immediately after and 6 weeks following 
an educational intervention and the study population 
was community pharmacists registered with the Nepal 
Chemist and Druggist Association (NCDA) at Lalitpur 
district [24].
Sampling method
The pharmacy shops were selected using systematic sam-
pling with a sampling interval of three where the first 
pharmacy was selected randomly between one and three. 
The sampling interval was three as we were selecting 75 
pharmacies from the 204 registered community pharma-
cies in the district.
Sample size calculation
For sample size calculation, we assumed that the knowl-
edge would be about 40% in our population of commu-
nity pharmacists. This was obtained from the results of 
the pilot test and also from the literature review [25].
Knowledge = 40%p = 0.4, q = 1− p = 0.6
N = [Zα2 × p × q/(M.E.)2]
where Zα  =  1.645 from normal table, two tailed at 
10% alpha or 90% confidence interval, P  =  Popula-
tion proportion, M.E  =  Margin of error  =  10%, So, 
n = (1.645)2 × (0.4) × (0.6)/(0.1)2 = 65
Non response rate = 10%
Total sample size required after provision for drop outs 
from the study = 65 + 10% of 65 = 71
Development of the questionnaire
The questionnaire included questions framed based on 
knowledge and attitude studies about pharmacovigilance 
and consumer pharmacovigilance conducted among 
community pharmacists in other countries. Manuscripts 
and published papers describing similar research and 
methodological issues were also studied [4, 27–30]. In 
the questionnaire, the issues addressed were the origin 
of pharmacovigilance in Nepal, progress and status of 
pharmacovigilance and the present system of pharma-
covigilance in the country. Information about reporting 
ADRs, who can report ADRs, location and functions of 
the national pharmacovigilance center were also cov-
ered. Processing of ADRs and information about the 
scales used to analyze ADRs were also addressed in the 
questionnaire.
Translation of the questionnaire
Additional file  1 shows the questionnaire developed in 
English. This questionnaire was translated into the Nepali 
language by two independent translators fluent in both 
languages and not associated with the study. The ques-
tionnaire was then back translated into English by two 
different individuals and the back translated version was 
compared with the original.
Pretesting of the questionnaire
The questionnaire was tested for readability and ease of 
understanding among ten CPs (four rural and six urban). 
The data obtained was not included in the study. Face val-
idation of the questionnaire was conducted by colleagues 
in the department. Then the questionnaire was sent to 
faculties of other departments for their inputs regarding 
readability and grammatical errors. Content validation 
was done by sending the questionnaire to content experts 
of pharmacovigilance within the country. Internal con-
sistency was measured by calculating Cronbach’s alpha 
value, which was 0.67 indicating good reliability.
Demographics
Gender, age, work experience, educational qualification 
and the location of the pharmacy were noted. Partici-
pant’s knowledge and attitude about pharmacovigilance 
and consumer pharmacovigilance was measured by 
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noting his/her agreement with a set of 21 statements 
using a Likert-type scale.
Information about the pharmacy
Information about the year of registration, number of 
patients visiting the pharmacy daily, number of books 
available for reference in the pharmacy, number of dis-
pensers and total number of brands of medicines in the 
pharmacy were noted from the respondents.
Scoring system
The scoring system used was: 5  =  strongly agree with 
the statement, 4 = agree, 3 = neutral, 2 = disagree and 
1 =  strongly disagree with the statement using a Likert 
scale. There were twelve statements for assessing knowl-
edge (maximum possible score of 60), and nine state-
ments for attitude (maximum possible score of 45). The 
maximum possible overall score obtained by adding the 
‘knowledge’, and ‘attitude’ scores was 105. The median 
and interquartile range were calculated for the ‘knowl-
edge’, ‘attitude’ and “overall” scores.
Conduct of the study
The questionnaire was administered personally by one of 
the investigator (RBP) visiting pharmacies in the study 
area. The community pharmacists were requested to 
complete the questionnaire in the presence of the inves-
tigator who could take back the completed questionnaire 
for analysis. This was used for collecting the baseline or 
pre intervention data. For the post intervention data, 
the questionnaire were administered to the participants 
immediately after the intervention session. Retention 
data were collected by visiting the participants individu-
ally in the same pharmacies 6 weeks after the educational 
intervention and employing the same procedure as that 
used for the pre-intervention data. Baseline knowledge 
and attitude of CPs was studied so that strengths and 
deficiencies could be noted and appropriate educational 
interventions planned. Knowledge and attitude was 
measured immediately after the educational interven-
tion, and retention of information was tested 6  weeks 
post intervention.
Educational intervention
The intervention included a session about pharmacovigi-
lance and consumer pharmacovigilance. They were also 
asked to share their views and opinions about the adverse 
drug reaction reporting form designed for community 
pharmacists. Informative posters were also displayed 
for information sharing about ADRs. Participants also 
learned about the existing pharmacovigilance system in 
Nepal and the importance of involving consumers in the 
existing system. The duration of the session was 2 h. The 
teaching learning aids used were power point presenta-
tion, posters and leaflets about ADRs. The session was 
interactive and the participants designed an adverse drug 
reaction reporting form to be used by community phar-
macists in the Nepali language.
Statistical analysis
The knowledge, attitude and overall scores were tested 
for normality of distribution using Shapiro–Wilk test. 
The samples were noted not to follow a normal distri-
bution so median and interquartile range and Wilcoxon 
Signed Rank Tests for Repeated Samples (non-paramet-
ric test) were used for comparing pre, post and retention 
scores. A p value less than 0.05 was taken as statistically 
significant. As the sample size was small KAP scores at 
the three points in time were compared only among a 
limited number of subgroups. The scores were compared 
among respondents grouped according to gender, loca-
tion and qualifications as we felt these were the most 
important characteristics and there was enough number 
of respondents in each subgroup. The collected data was 
analyzed using SPSS version 20.0 for Windows.
Ethical considerations
The study was approved by the Institutional Research 
Committee of KIST Medical College. All CPs were 
informed and explained about the aims and objectives 
of the study and invited to participate. Written informed 
consent was obtained from all participants.
Results
Seventy-five of the 86 invited respondents partici-
pated and the response rate was 87%. Table 1 shows the 
respondent’s demographic characteristics. Male respond-
ents were greater in number compared to females and 
respondents of age group 21–30  years were more than 
respondents from other age groups. Thirty-five respond-
ents (46%) used Current Index of Medical Specialties 
(CIMS) as a reference book in the pharmacy while 13 
respondents (17%) used Nepal drug review (NDR) as 
their reference. Twenty-five respondents (30%) had two 
people for dispensing medicines whereas a single per-
son for dispensing was seen with 21 (28%) respondents. 
These people were alwayszfzfs present in the pharmacy.
Table 2 shows the knowledge, attitude and total (over-
all) scores at pre, post and retention stages with regard 
to the educational intervention for the participants. The 
knowledge score increased both immediately after and 
six weeks following the intervention. The overall score 
decreased 6  weeks post-intervention as attitude score 
had decreased significantly during the period.
Table  3 shows differences in overall, knowledge and 
attitude scores at pre, post and retention stages of the 
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educational intervention according to gender and loca-
tion of the community pharmacists as these variables had 
more than 30 samples in each category.
Gender
The median knowledge scores improved immediately 
after the intervention and also six weeks following the 
educational intervention compared to the baseline among 
both genders. Males showed a consistent improvement 
in knowledge scores. Attitude scores improved after the 
intervention compared to baseline but the improvement 
was not significant 6  weeks after intervention among 
females. The overall scores also improved significantly 
after the intervention.
Rural and urban location
Knowledge scores among community pharmacists work-
ing at rural and urban pharmacies improved significantly 
immediately after and 6  weeks post intervention. The 
attitude scores post intervention also improved but the 
improvement was higher among pharmacists working 
in rural areas. The overall scores improved significantly 
immediately post intervention.
Discussion
The knowledge of community pharmacists in the present 
study regarding pharmacovigilance was low (47.5%). The 
topic of consumer pharmacovigilance was also new and 
not many were aware about it. This finding was similar 
to that observed in previous studies [26–31]. Community 
pharmacy practice is well developed in nations like the 
United Kingdom and Australia, where pharmacists are 
well aware of pharmacovigilance and consumer pharma-
covigilance systems [32].
A possible reason for the low knowledge and attitude 
scores in the present study could be that not all persons 
working in community pharmacies were from the phar-
macy profession. Some were nurses, community medi-
cine auxiliaries (CMAs) while others were pharmacy 
professionals. CMAs are paramedical professionals who 
undergo basic medical training for eighteen months. 
They are capable of diagnosing and treating minor ill-
nesses and can also refer the patients for higher special-
ized care services if needed and they do not have any 
legal authority to dispense medicines unless they have 
completed the DDA orientation training course [18]. In 
the existing pharmacovigilance system of Nepal, phar-
macists are allowed to report ADRs in the hospital set-
tings through the regional pharmacovigilance centres, 
but it has not yet being started for community settings. 
Inadequate knowledge of ADR reporting systems among 
community pharmacists has also been reported in the 
literature. In Saudi Arabia, 86.8% of community phar-
macists surveyed were not aware of the country’s ADRs 
reporting program, and another study in Iran indicated 
that only 30% of pharmacists were aware about the Ira-
nian pharmacovigilance centre [33–35].
Community pharmacists should be educated about 
pharmacovigilance in Nepal to improve their knowledge. 
Lack of knowledge about what is an adverse drug reac-
tion, what is to be reported, who can and should report, 
when to report, how to report, where to report, whom 
to report and lack of availability of ADR reporting forms 
for community pharmacists as well as for consumers 
can hamper ADR reporting in community settings. The 




 Male 45 (60)
 Female 30 (40)
Age (in years)
 Below 20 12 (16)
 21–30 39 (52)
 >3 24 (32)
Work experience (year)
 <5 23 (30.6)
 5–10 25 (33.4)
 >10 27 (36)
Location
 Rural 40 (53.3)
 Urban 35 (46.7)
Reference books available in the pharmacy
 CIMS 35 (46.6)
 NDR 13 (17.4)
 Both CIMS and NDR 16 (21.4)
 None 11 (14.6)
Table 2 Differences in knowledge, attitude and total (overall) (shown as median (interquartile range) scores at pre, post 
and retention stages of the educational intervention
Domain Pre Post p value Pre Retention p value Post Retention p value
Knowledge 39 (44–46) 44 (44–44) <0.001 41 (40–41) 46 (43–46) <0.001 46 (46–46) 53 (49–53) 0.254
Attitude 42 (40–44) 45 (44–46) <0.001 42 (40–44) 35 (34–36) <0.001 45 (44–46) 35 (34–36) <0.001
Overall 81 (75–83) 89 (86–92) <0.001 81 (75–83) 80 (77–83) 0.901 89 (86–92) 80 (77–83) <0.001
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national pharmacovigilance program should use various 
interventional strategies followed by other countries for 
improving ADR reporting [36–40].
In our study, the attitude scores were good. In a study 
done by Khalili et  al. [43], the attitude towards ADR 
reporting among community pharmacists improved after 
an intervention which has some similarities with studies 
done in the UK and other countries [11, 41–43], where 
pharmacists showed positive attitude towards ADR 
reporting. However, a study in Gujarat, India explor-
ing KAP scores regarding pharmacovigilance among 
community pharmacists revealed a poor score and the 
authors had recommended an educational intervention 
[44].
The results of our study has shown that the educational 
program was effective in improving the knowledge and 
attitude of CPs towards pharmacovigilance. Similar find-
ings were reported by previous studies [43, 45]. A statis-
tical difference was noted between respondents’ gender 
and the responses to the statement adverse drug reac-
tions are one of the major causes of death in the world 
and for the sentence about verbal reporting and writ-
ten forms being preferred methods for ADR reporting 
(p  <  0.001). Significant differences were also seen with 
the statement regarding involvement of Pharmaceutical 
industries in reporting ADRs and about the location of 
the national pharmacovigilance centre. Participant’s age, 
work experience, involvement in any kind of educational 
intervention has shown an impact on pharmacovigilance 
activities and ADR reporting as shown in other studies 
[30, 43, 45].
The baseline knowledge and attitude scores for both 
males and females were nearly same but the scores were 
better in females after the intervention. This was similar 
to that seen in a study done in Oman [46].
Limitations
The study participants were from Lalitpur district and 
the result may not be generalizable to pharmacists other 
districts. Involving more pharmacist from the other two 
districts of the Kathmandu valley (Kathmandu and Bhak-
tapur) would have given a better understanding about 
the perception of community pharmacists from the val-
ley. Also the overall sample was small and the interven-
tion may not have been the only factor which changed 
attitudes, as no control group was used. Also some of the 
Table 3 Difference in  scores among  selected subgroups of  community pharmacists before  (pre-test), immediately 
after (post-test) and six weeks following (retention) an educational intervention






























  Male 81 (75–83) 89 (85–92) <0.0 81 (75–83) 80 (77–83) 1.000 89 (85–92) 80 (77–83) <0.001
  Female 80 (75–83) 91.5 (81–93) <0.001 80 (75–83) 80 (75–82) 0.769 91.5 (81–93) 80 (75–82) <0.001
 Location
  Rural 80 (75–93) 90 (87–92.75) <0.001 80 (75–93) 81 (79–93) 0.168 90 (87–92.75) 81 (79–93) <0.001
  Urban 82 (76–86) 89 (85–92) <0.001 82 (76–86) 80 (75–93) 0.267 89 (85–92) 80 (75–93) <0.001
Knowledge score
 Gender
  Male 39 (37–40) 44 (41–47) <0.001 39 (37–40) 46 (42–48) <0.001 44 (41–47) 46 (42–48) 0.097
  Female 39 (37–42) 44 (43–45) <0.001 39 (37–42) 45 (39–47) <0.001 44 (43–45) 45 (39–47) 0.837
 Location
  Rural 39 (44–46) 44 (44–44) <0.001 39 (44–46) 46 (43–47) <0.001 44 (44–44) 46 (43–47) 0.206
  Urban 38 (33–46) 43 (43–44) <0.002 38 (33–46) 46 (42–47) <0.001 43 (43–44) 46 (42–47) 0.761
Attitude score
 Gender
  Male 43 (37–44) 44 (43–47) 0.012 43 (37–44) 35 (31–37) 0.003 44 (43–47) 35 (31–37) <0.001
  Female 41 (35–44) 46 (44–48) <0.001 41 (35–44) 35 (31–37) <0.001 46 (44–48) 35 (31–37) <0.001
 Location
  Rural 41 (35–44) 45 (43–47) <0.001 41 (35–44) 35 (31–38) <0.001 45 (43–47) 35 (31–38) <0.001
  Urban 43 (38–44) 45 (43–48) 0.039 43 (38–44) 34 (31–37) <0.001 45 (43–48) 34 (31–37) <0.001
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statements in the questionnaire were positive and may 
have influenced the participants’ response.
Conclusion
The educational intervention improved the phar-
macovigilance knowledge and attitude scores of the 
community pharmacists. The present study revealed 
an improvement in the knowledge scores for males 
and female participants whereas, the attitude scores 
improved among female respondents. Knowledge and 
attitude scores were higher among pharmacists working 
in rural areas.
Similar studies should be conducted among community 
pharmacists in other districts of Nepal. The perception 
of consumers regarding reporting ADRs to community 
pharmacists should also be studied.
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